PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. - Wikidata - wikimedia - TriplyDB

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

http://www.wikidata.org/entity/Q33674643

about

The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers Capillary Isoelectric Focusing of Akt Isoforms Identifies Highly Dynamic Phosphorylation in Neuronal Cells and Brain Tissue NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Drugging PI3K in cancer: refining targets and therapeutic strategies ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.Molecules in medicine mini-review: isoforms of PI3K in biology and disease.CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.The PI3K Pathway in Human Disease.Inhibition of PTEN activity aggravates cisplatin-induced acute kidney injury.First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.

P2860

Q34262144-28E1AA19-FF11-4FF8-983A-7E53DAFE7D6B Q34590266-EFC0A4BB-A567-4F7F-80E2-2E714C6F670F Q34608239-1A07E0A4-0558-497C-983D-AB9FB2A34C00 Q35236484-CFDDF79A-15D2-4246-A6BA-F9429B27BA46 Q35260766-1156C4B0-2436-4643-8295-DD4FB8696FD3 Q36840275-D45F0B43-4648-4D6D-8DEA-BD847437B61C Q36876219-6C3872B0-88F4-4F5A-A02E-41F363498A29 Q37268717-72A9547B-CC2A-4624-9150-ED2DAB355902 Q38265574-0A5B1A0C-F705-4C53-8275-8649FCAB69E5 Q38539217-0B5EA533-5E33-49A1-9EFF-2891530CFBC3 Q38637153-BEADCA0E-13B2-4A33-AD56-85542371921C Q38666875-E0C23A3C-01D8-469B-96EB-9EA1EC056BD6 Q38672092-40E78C0F-68E3-4D86-B118-A6CAC06EBDA2 Q38718336-209C455C-742F-495C-A9C7-00A87A212147 Q38745816-54CB0EFE-5780-43D1-BACB-72DA99DF965B Q42030378-F5FF1770-5F31-4946-961F-48228341D3E6 Q42118139-5F9A6A9F-3F96-4447-9D88-6D2C08AEFF80 Q46546002-F5AD1014-77C8-4AE8-A8CB-590C43B068BD Q47160630-82F6457B-8765-4EFD-8564-9931E9D2604D Q48246561-66CCAC5C-D027-46BB-A264-4D491D405BDB Q52951832-972D1EF8-0426-446C-B07E-760214916891

P2860

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

http://www.wikidata.org/entity/Q33674643

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@ast

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@en

type

label

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@ast

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@en

prefLabel

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@ast

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@en

P1433

Q33674643-C6C88EBC-C307-493E-858C-6DE1FE8CBF18

P1476

Q33674643-78C6E957-E87D-403E-8572-664B36BED81B

P2093

Q33674643-2B9D47CA-2626-4701-84A3-26DF26971749

Q33674643-5B86EB41-036B-45BF-A21B-D520CC123AE7

Q33674643-9C226F0D-8D64-4685-B05C-69DBE9B993D7

Q33674643-E07614DA-4C96-4C4E-B34B-78F7B639CB86

Q33674643-E55FF2A3-0D5C-4527-ADB2-50C812E7BC67

Q33674643-F7575E26-7A2D-4CFF-AE6F-D39BE92CBDCC

Q33674643-F907F341-2AD8-42F5-A052-0FDD7D8FE11D

P2860

Q33674643-00F9F984-3C84-4F41-8650-7AFD6754AAD0

Q33674643-0290C4CE-C3DF-4A20-A72C-35E89F13D4F9

Q33674643-110C35B2-68E0-451B-B915-EDEFBCF57693

Q33674643-12BEA249-4D70-41FE-B0B6-8017D857D380

Q33674643-16F4382C-BC2A-4185-A518-92A22F7BB1C9

Q33674643-17E4931A-47C6-402C-A97D-AFB4E69C6D8B

Q33674643-208EB9FE-7179-4330-89F6-285C6383F403

Q33674643-3091A2A8-CC3F-4B86-8638-10D3BF120969

Q33674643-397A0721-2787-4415-83E3-46B1D1130FD4

Q33674643-408D81D5-2263-48C6-8CDC-89E763F290A8

P304

Q33674643-8E9B1AE9-B3EC-4BCD-8943-08ACAF5A8B86

P31

Q33674643-BEF11F70-7636-4024-A977-FDFFB612C32C

P356

Q33674643-B886B189-3161-45AF-A182-DFC6D293DA56

P407

Q33674643-554B962F-FAFC-48EE-AE49-5788D16161DC

P433

Q33674643-D69FCBAB-3109-42FB-AC9B-8BC45574EDD0

P478

Q33674643-D38AC301-1001-4856-8DE0-24C159BDAEB8

P577

Q33674643-62E0DE11-A9C7-43D4-B837-AFED2FFD0B81

P5875

Q33674643-DE3AE751-A249-47B6-AB2E-EC2E3B0DF4A6

P698

Q33674643-B7C2FA02-AC68-498F-9F33-C43A95374A64

P932

Q33674643-F823B676-ACAD-46EA-8C81-1A6952DC9ACA

P356

PNAS.1323004111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

@en

P2093

Fabienne Schmit

http://www.w3.org/2001/XMLSchema#string

Jean J Zhao

http://www.w3.org/2001/XMLSchema#string

Qi Wang

http://www.w3.org/2001/XMLSchema#string

Sen Zhang

http://www.w3.org/2001/XMLSchema#string

Tamara Utermark

http://www.w3.org/2001/XMLSchema#string

Thanh Von

http://www.w3.org/2001/XMLSchema#string

Thomas M Roberts

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

Should individual PI3 kinase isoforms be targeted in cancer?

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

The genomic landscapes of human breast and colorectal cancers

High frequency of mutations of the PIK3CA gene in human cancers

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

PI3K pathway alterations in cancer: variations on a theme

P304

6395-6400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1323004111

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261745461

http://www.w3.org/2001/XMLSchema#string

P698

24737887

http://www.w3.org/2001/XMLSchema#string

P932

4035990

http://www.w3.org/2001/XMLSchema#string